Adults 18 to 60, any sex, with Schizophrenia or Schizoaffective Disorder. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Visual Attention to Static FacesPrimary· Assessment will be completed 30 minutes after completion of the active/sham stimulation
Visual attention measured via eye-tracking (percentage of time attending to investigator designated AOIs) when viewing static, emotional faces (stimuli: Emotion Recognition - 40). AOIs for static faces will be defined as core facial features (i.e. eyes, nose, mouth).
Group
Value
95% CI
Anodal Stimulation tDCS to rTPJ
0.54
± 0.15
Sham tDCS to rTPJ
0.52
± 0.15
Anodal Stimulation tDCS to dmPFC
0.57
± 0.13
Sham tDCS to dmPFC
0.53
± 0.14
Visual Attention to Dynamic ActorPrimary· Assessment will be completed 30 minutes after completion of the active/sham stimulation
Visual attention measured via eye-tracking(percentage of time attending to investigator designated AOIs) when viewing videos of a single actor (stimuli: Bell Lysaker Emotion Recognition Task). AOIs for this task will be defined as core facial features (i.e. eyes, nose, and mouth).
Group
Value
95% CI
Anodal Stimulation tDCS to rTPJ
0.47
± 0.12
Sham tDCS to rTPJ
0.46
± 0.11
Anodal Stimulation tDCS to dmPFC
0.47
± 0.11
Sham tDCS to dmPFC
0.47
± 0.11
Visual Attention to Dynamic Social ScenesPrimary· Assessment will be completed 30 minutes after completion of the active/sham stimulation
Visual attention measured via eye-tracking (percentage of time attending to investigator designated AOIs) when viewing videos of two or more actors in a scene (stimuli: The Awareness of Social Inference Task Part 3, Version A). AOIs for this task will be defined as salient social and contextual stimuli (e.g. social stimuli are faces of actors, while contextually salient stimuli include items actors are talking about, such as a plate full of food or an empty wallet).
Group
Value
95% CI
Anodal Stimulation tDCS to rTPJ
0.22
± 0.06
Sham tDCS to rTPJ
0.23
± 0.07
Anodal Stimulation tDCS to dmPFC
0.26
± 0.07
Sham tDCS to dmPFC
0.25
± 0.07
Fixation StabilizationSecondary· Assessment will be completed 30 minutes after completion of the active/sham stimulation
Stabilization of visual fixation on fixation circle positioned in middle of screen. Participants will be placed in front of an eyetracking device and asked to keep their eyes focused on a circle in the middle of the screen. Stabilization will be measured via eye-tracking as the deviation from a single point on screen, calculated by assessing the sum of squares of both the x and y axis (output from eyetracking device). Higher number indicates more movement, and thus less stabilization.
Group
Value
95% CI
Anodal Stimulation tDCS to rTPJ
0.10
± 0.24
Sham tDCS to rTPJ
0.08
± 0.14
Anodal Stimulation tDCS to dmPFC
0.05
± 0.10
Sham tDCS to dmPFC
0.07
± 0.14
Adverse events — posted to ClinicalTrials.gov
Time frame: From time of visit 1 through the follow up phone call (Average time around 10 days, longest duration 29 days).
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This study investigates whether visual attention can be improved in individuals with schizophrenia by stimulating the brain via transcranial Direct Current Stimulation (tDCS).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au
· Phase 3
· recruiting
NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
· Phase 2
· recruiting
NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
· recruiting
NCT06758414 — CBT-CP for Veterans With SMI
· NA
· recruiting
NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis
· NA
· recruiting
Other The University of Texas at Dallas trials
Trials by the same sponsor.
NCT07534397 — Treatment of Cognitive and Sensorimotor Deficits in Parkinson's Disease With High Definition Transcranial Direct Current
· NA
· not yet recruiting
NCT07354139 — Using Non-invasive Brain Stimulation to Explore Potential Treatments to Reduce Speech Errors in Adults Who Stutter
· NA
· recruiting
NCT07206550 — The Role of Framing and Choice Architecture in Patients' Reactions and EHR Error Discovery and Reporting
· NA
· enrolling by invitation
NCT06731452 — Exploring Neurophysiological Markers of Brain Health
· NA
· recruiting
NCT06724887 — Brain Health on College Campuses
· NA
· recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of Texas at Dallas
Last refreshed: 13 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03880227.